Compare TROO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROO | ZURA |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | Hong Kong | United States |
| Employees | N/A | 30 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.1M | 521.8M |
| IPO Year | 2008 | N/A |
| Metric | TROO | ZURA |
|---|---|---|
| Price | $2.28 | $6.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 153.7K | ★ 502.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.99 |
| 52 Week High | $5.28 | $7.25 |
| Indicator | TROO | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 48.93 |
| Support Level | $0.74 | $5.49 |
| Resistance Level | $2.74 | $6.99 |
| Average True Range (ATR) | 0.29 | 0.48 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 46.84 | 57.97 |
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.